LUO Qian, Kathy

• Citations: 7,488, h-index: 44, i10-index: 80 (Google Scholar) (01-08-2024) (https://scholar.google.com.sg/citations?user=VyK5XakAAAAJ&hl=en)
• Published journal articles: 104, book chapter: 1, conference papers: 10.
• Conference presentations and invited talks: 120.
• Total grants obtained as a PI/Co-PI: 35; funding: MOP 98 million (US$ 12.1 million).
• At Macau (2016-now) as a PI: 15 grants; funding: MOP 23.5 million (US$ 2.9 million).
• Granted patents: 8 (5 USA, 2 China, 1 Singapore), pending patents: 3.
• Best Teacher (Excellence in Service, 2018 and 2021; Excellence in Research, 2022) from Faculty of Health Sciences, University of Macau.
• Supervised students/staff in career: 9 Postdocs, 33 Ph.D. students, 24 M.S. students, and 9 RAs.

Peer-Reviewed Journal Articles (*: Luo KQ as corresponding or co-corresponding authors; IF refers to IF of 2022 or 5-year IF.)

1. Chen JL, Gu ZY, Jia XH, Liu JZ, Wu X, Yuan MH, Bai LP, Luo KQ, Xia X, Yin D, Wang J, Zhu XM* (2024) Kidney-targeted antioxidant salvianolic acid B nanoparticles restoring lysosome homeostasis for acute kidney injury therapy. Chemical Engineering Journal 490 (2024) 151811. Pages 1-14. Available online 30 April 2024. DOI: https://doi.org/10.1016/j.cej.2024.151811. IF: 15.1.
2. Yi Y, Qin G, Yang H, Jia H, Zheng D, Zhang Z, Ye S, Liu TM, Luo KQ, Deng CX, Xu RH* (2024) Mesenchymal stromal cells increase the natural killer resistance of circulating tumor cells via intercellular signaling of cGAS-STING-IFNβ-HLA. Advanced Science. Page 1-18. April 18, 2024. DOI: http://doi.org/10.1002/advs.202400888. 5-year IF: 16.7.
3. Jia H, Yang H, Luo KQ* (2024) Zebrafish live imaging reveals only around 2% rather than 50% of motor neurons die through apoptosis during development. Been sent out for peer review in eLife. The preprint of this manuscript (10.1101/2024.01.26.577434) has been posted on bioRxiv: https://biorxiv.org/cgi/content/short/2024.01.26.577434v1, Jan 29, 2024. IF: 8.7.
4. Jia H, Yang H, Xiong H, Luo KQ* (2023) NK cell exhaustion in the tumor microenvironment. Frontiers in Immunology, 2023, 14:1-8. 5-year IF: 8.0.
5. Huang S, Xing F, Dai Y, Zhang Z, Zhou G, Yang S, Liu YC, Yuan Z, Luo KQ, Ying T, Chu D*, Liu TM*, Deng CX*, Zhao Q* (2023) Navigating chimeric antigen receptor-engineered natural killer cells as drug carriers via three-dimensional mapping of the tumor microenvironment. Journal of Controlled Release, 362:524-535. IF: 10.8.
6. Tong H, Li K, Zhou M, Wu R, Yang H, Peng Z, Zhao Q, Luo KQ* (2023) Coculture of cancer cells with platelets increases their survival and metastasis by activating the TGFβ/Smad/PAI-1 and PI3K/AKT pathways. International Journal of Biological Sciences, 19(13):4259-4277. IF: 9.2.
7. Hao M, Huang B, Wu R, Peng Z, Luo KQ* (2023) The interaction between macrophages and triple-negative breast cancer cells induces ROS-mediated interleukin 1α expression to enhance tumorigenesis and metastasis. Advanced Science, 2023, 2302857, pages 1-20. 5-year IF: 16.7.
8. Chen JL, Jia XH, Xia X, Wu X, Xu YN Xu, Yuan G, Gu ZY, Luo KQ, Yuan MH, Jiang R, Wang J, Zhu XM* (2023) Codelivery of vorinostat and chloroquine by autophagy-inhibitory hollow ZrO2 nanoshells for synergistic combination chemotherapy. Chemical Engineering Journal, 471:144740, pages 1-17. IF: 15.1.
9. Zhou M, Li K, Luo KQ* (2023) Shear stress drives the cleavage activation of protease-activated receptor 2 by PRSS3/mesotrypsin to promote invasion and metastasis of circulating lung cancer cells. Advanced Science, 2023, 10:2301059, pages 1-21. 5-year IF: 16.7.
10. Yan Y, Xing F, Cao J, Hu Y, Li L, Gao Z, Jia H, Miao K, Shao F, Deng CX*, Luo KQ*, Lee LT*, Liu TM* (2023) Fluorescence intensity and lifetime imaging of lipofuscin-like autofluorescence for label-free predicting clinical drug response in cancer. Redox Biology, 59 (2023) 102578, pages 1-12. 5 year-IF: 11.9.
11. Yang H, Jia H, Zhao Q, Luo KQ* (2022) Visualization of natural killer cell-mediated killing of cancer cells at single-cell resolution in live zebrafish. Biosensors and Bioelectronics, 216, 114616:1-9. IF: 12.6.
12. Yeung CK, Yan Y, Yan L, Duan Y, Li E, Huang B, Lu K, Li K, Zhou M, Zhang L, Wu Y, Luo KQ, Ji W, Xu RH*, Si W* (2022) Preclinical safety evaluation and tracing of human mesenchymal stromal cell spheroids following intravenous injection into cynomolgus monkeys. Biomaterials. 289, 121759:1-14. IF: 14.0.
13. Tao J, Wei Z, Cheng Y, Xu, M, Li Q, Lee SMY, Ge W, Luo KQ, Wang X, Zheng Y* (2022) Apoptosis-sensing Xenograft Zebrafish Tumor Model for Anticancer Evaluation of Redox-responsive Crosslinked Pluronic Micelles. ACS Applied Materials & Interfaces, 14(35) 39775-39786. IF: 9.5.
14. Peng Z, Hao M, Tong H, Yang H, Huang B, Zhang Z, Luo KQ* (2022) The interactions between integrin α5β1 of liver cancer cells and fibronectin of fibroblasts promote tumor growth and angiogenesis. International Journal of Biological Sciences, 18(13):5019-5037. IF: 9.2.
15. Li T, Luo KQ* (2022) Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants. International Journal of Biological Sciences, 18(12):4642-4647. IF: 9.2.
16. Regmi S, Poudel C, Adhikari R, Luo KQ* (2022) Applications of microfluidics and organ on chips in cancer research. Biosensors, 12(7):459, pages 1-29. IF: 5.4.
17. Wu X, Wang L, Xu Y-N, Chen J-L, Luo KQ, Yuan M-H, Li J, Yuan G, Gu Z-Y, Jia X-H, Chen X, Zhu X-M*, Jiang R* (2022). Chemo-Phototherapy with Carfilzomib-Encapsulated TiN Nanoshells Suppressing Tumor Growth and Lymphatic Metastasis. Small, 18 (29):2200522, pages 1-15. IF: 13.3.
18. Huang B, Hao M, Li C, Luo KQ* (2022) Acetyltanshinone IIA reduces the synthesis of cell cycle-related proteins by degrading p70S6K and subsequently inhibits drug-resistant lung cancer cell growth. Pharmacological Research, 179:106209, pages 1-18. IF: 9.3.
19. Xu M, Tao J, Wei Z, Cheng Q, Yang H, Lee SMY, Luo KQ, Ge W, Wang R*, Zheng Y* (2022) Visualization of host-guest interactions driven bioorthogonal homing effects at the single cell level in vivo. Nano Today, 43:101450, pages 1-8. IF: 17.4.
20. Luo M, Fu A, Wu R, Wei N, Song K, Lim S, Luo KQ* (2022) High expression of G6PD increases doxorubicin resistance in triple negative breast cancer cells by maintaining GSH level. International Journal of Biological Sciences, 18(3):1120-1133. IF: 9.2.
21. Liu J, Yang S, Cao B, Zhou G, Zhang F, Wang Y, Wang R, Zhu L, Meng Y, Hu C, Liang H, Lin X, Zhu K, Chen G, Luo KQ, Di L, Zhao Q* (2021) Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Journal of Hematology & Oncology, 14(1):1-18. IF: 28.5.
22. Li K, Wu R, Zhou M, Tong H, Luo KQ* (2021) Desmosomal proteins DSC2 and PKP1 promote cancer cells survival and metastasis by increasing cluster formation in circulatory system. Science Advances, 7(40):eabg7265, pages 1-20. 5-year IF: 15.4.
23. Xing F, Liu YC, Huang S, Lyu X, Su SM, Chan UI, Wu PC, Yan Y, Ai N, Li J, Zhao M, Rajendran BK, Liu J, Shao F, Sun H, Choi TK, Zhu W, Luo G, Liu S, Xu DL, Chan KL, Zhao Q, Miao K, Luo KQ, Ge W, Xu X, Wang G*, Liu TM*, Deng C* (2021) Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform. Theronostics, 11(19), 9415-9430. IF: 12.4.
24. Jia H, Luo KQ* (2021) Fluorescence resonance energy transfer-based sensor zebrafish for detecting toxic agents with single-cell sensitivity. Journal of Hazardous Materials, 408:124826, pages 1-9. IF: 13.6.
25. Wu R, Luo KQ* (2021) Developing effective siRNAs to reduce the expression of key viral genes of COVID-19. International Journal of Biological Sciences, 17(6):1521-1529. IF: 9.2.
26. Wu R, Li K, Yuan M, Luo KQ* (2021) Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells. Oncogene, 40(12):2165-2181. 5-year IF: 8.8.
27. Sheraton MV, Chiew GGY, Melnikov V, Tan EY, Luo KQ*, Verma N*, Sloot PMA* (2020) Emergence of spatio-temporal variations in chemotherapeutic drug efficacy: in-vitro and in-Silico 3D tumour spheroid studies. BMC Cancer, 20(1):1201, pages 1-16. 5-year IF: 4.3.
28. Huang B, Yip WK, Wei, N, Luo KQ* (2020) Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells. Cancer Letters, 490:1-11. IF: 9.7.
29. Jia H, Song YL, Huang B, Wei G, Luo KQ* (2020) Engineered sensor zebrafish for fast detection and real-time tracking of apoptosis at single-cell resolution in live animals. ACS Sensors, 5(3):823-830. 5-year IF: 9.0.

Full list of publications: https://fhs.um.edu.mo/en/prof-kathy-qian-luo-full-publications

Granted Patents

1. Luo KQ, Xu J, Method of preparing soy isoflavone nanoparticles by precipitation with compressed antisolvent (PCA) using a supercritical fluid. US Patent No.: US 9,259396 B2, granted on Feb 16, 2016.
2. Luo KQ, Yu T, Luo HW, 作为抗癌剂的乙酰丹参酮IIA(ATA), China Patent No.: 2, granted on Feb 3, 2016.
3. Luo KQ, Yu T, Luo HW, Acetyltanshinone IIA (ATA) as anticancer agent. US Patent No.: US 9,226,912 B2, granted on Jan. 5, 2016.
4. Luo KQ, Yu T, Luo HW, Acetyltanshinone IIA (ATA) as anticancer agent. Singapore Patent No. 193492, granted on August 15, 2014.
5. Ng KM, Luo Q, Zhang EJ, Harjo B, A health care product containing isoflavone aglycones and method of preparing the same. US Patent No. US 7,553,505 B2, granted on June 30, 2009.
6. Chang DC, Luo KQ, Nucleic Acid encoding fluorescent protein constructs and methods for detecting apoptosis. US Patent US 7,354,735, granted on April 8, 2008.
7. Chang DC, Luo Q, Modified fluorescent protein for detecting proteases activity. US Patent No. US 7,049,400, granted on May 23, 2006.
8. Chang DC, Luo KQ, 基于绿色荧光蛋白检测细胞凋亡的方法. China Patent No. 021204276, granted on May 3, 2006.

Filed Patents

1. Luo Qian and Huang Bin, 乙酰丹参酮IIA在制备治疗肺癌的药物中的应用及治疗肺癌的药物, China Patent Application No., 202210189883X, filing date: March 01, 2022.
2. Luo Qian and Huang Bin, 乙酰丹参酮IIA在制备治疗肺癌的药物中的应用及治疗肺癌的药物, PCT Application No. PCT/CN2022/117849, filing date, Sept. 08, 2022.
3. Luo Qian and Huang Bin, Use of acetyltanshinone IIA in preparation of medicament for treating lung cancer and medicament for treating lung cancer. US patent application No. 18/384,952, filing date, Oct. 30, 2023.

University of Macau

University Level:

1. Chair of Animal Research Ethics of UM (2016-2021)
2. University-level Academic Staff Promotion Advisory Committee 2019/2020
3. UM Senate (2016-2018)
4. Research Committee of UM (2016-2018)
5. President of the Presidium of the General Assembly of the Academic Staff Association of UM (2017-2019)
6. Ad Hoc Selection Committee for Emeritus Professor of UM (2017-2018)
7. UM-Selection Committee for Macau Fellow (2018)
8. UM-Selection Committee for Macau Science and Technology Awards for Postgraduates (2018)
9. Chairing PhD Oral Defenses for various faculty and academic units of UM (2018-present)
10. Ac-hoc member of the Patent Review Panel (2018-present)
11. General Education Programme Review Committee (GEPRC) (2022-present)
12. Investigation Panel for Student Affairs (2019)
13. Faculty-level Academic Staff Promotion Advisory Panel of AMSV (2017)
14. Faculty-level Academic Staff Promotion Advisory Panel of ICMS (2019)
15. Equipment Committee for UM Henequin Research Center (2019-2020)
16. Affiliated with a Residential College, CKPC (2016-present)

Faculty Level:

17. Head of the Department of Biomedical Sciences (2023-present)
18. Associate Head of the Department of Biomedical Sciences (2021-2023)
19. Coordinator of undergraduate programme of FHS (2019-2021)
20. Faculty Executive Committee (FEC) (2016-2021, 2023-present)
21. Chair of the Programme Management Committee (PMC) (2019-2021)
22. Faculty Academic Leave Committee (2023-present)
23. Faculty Academic Staff Promotion Advisory Committee (2019-2020, 2023-present)
24. Faculty Academic Personnel Committee (2017-present)
25. Faculty Contract Renewal Committee (2016-present)
26. Selection Committee for Academic Faculty Recruitment (2019-present)
27. Selection Committee for Macau Science and Technology Awards 2018 (Postgraduates)
28. Selection Committee for UM Macau Talent Program (UMMTP) (2018-present)
29. Selection Committee for Macau Fellow (2016-present)
30. Chair of the Recruitment Committee for Administrative Staff (2018-present)
31. Committee for the 10^th Year Celebration of FHS (August 2022-December 2023)
32. Ad Hoc Committee for FHS Best Paper Award 2021 (18/10/2021)
33. As a judge for the oral presentations in the 6^th Symposium on Biomedical Sciences for Students, Postdoctoral Fellows and Research Assistants 2022 in Macau (2022-present)
34. Graduate Studies Committee (2016-present)
35. Equipment Committee of FHS and ICMS (2016-present)
36. Coordinator of Final Year Project (2016-2021)
37. Postgraduate Academic Committee (2016-present)
38. Member of the Academic Council (AC) of FHS (2016-present)
39. Committee of Five-year Programme Review of FHS (2019-2020)
40. Reviewed grant applications submitted to MoE-FSCPO (2021-present) and MYRG (2024)

Scientific Communities

Conference Committees:

1. Session Chair, 9^th Macau Symposium on Biomedical Sciences. June 13-17, 2023, Macau.
2. Judge for the 6^th Symposium on Biomedical Sciences for Students, Postdoctoral Fellows and Research Assistants, April 6, 2022, Macau.
3. Session Chair, Precision Medicine Symposium. June 26-27, 2019, Macau.
4. Session Chair, 6^th Macau Symposium on Biomedical Sciences. June 12-13, 2019, Macau.
5. Session Chair, 5^th Macau Symposium on Biomedical Sciences. June 8-9, 2018, Macau.
6. Organizing Committee, 3^rd World Conference on the Pharmacology of Natural and Traditional Medicine 2015, July 22-24, Singapore
7. Technical Program Committee (TPC) for MicroTAS 2014, October 26-30, 2014, San Antonio, Texas, USA
8. Session Chair, 15^th International Conference on Biomedical Engineering (ICBME 2013), December 4-7, 2013, Singapore
9. Coordinator of the NTU-SCBE Symposium on Drug Discovery, Drug Delivery and Regenerative Medicine at the 6^th Annual BioPharma Asia Convention, March 19, 2013, Singapore
10. Session Chair, The HKUST International Conference on Biomedical Engineering, Jan 10-12, 2013, Hong Kong
11. Organizing Committee, 2^nd International Conference on Cellular and Molecular Bioengineering (ICCMB2), August 2010, Singapore
12. Session Chair, International Conference on Recent Development in Chinese Herbal Medicine, January 2010, Singapore
13. Organizing Committee, 7^th International Conference of Modernization of Chinese Medicine & Health Products, August 2008, Hong Kong
14. Organizing Committee, 6^th International Conference of Modernization of Chinese Medicine & Health Products, August 2007, Hong Kong

Reviewer for Grant Applications:

1. European Research Council Consolidator Grant
2. Medical Research Council of UK
3. Research Grants Council (RGC) of Hong Kong, Funding Scheme: GRF/ECS
4. Health and Medical Research Fund of Hong Kong (HMRF)
5. National Research Foundation of Singapore Competitive Research Programme
6. Ministry of Education, Singapore, Academic Research Fund Tier 2
7. Ministry of Education, Singapore, Academic Research Fund Tier 1
8. Ministry of Education, Singapore, Translation and Innovation Fund
9. Agency for Science, Technology and Research, Nanyang Technological University, and National Health Group Skin Research Grant
10. Nanyang Technological University iFood Research Grant

Reviewer for 24 International Journals:

1. Molecular Cancer (IF: 37.3)
2. Advanced Science (IF: 15.1)
3. Journal of the American Chemical Society (JACS, IF: 15.0)
4. Biomaterials (IF: 14)
5. Cancer Letters (IF: 9.7)
6. International Journal of Biological Sciences (IF: 9.2)
7. Biotechnology Progress
8. Cancer Chemotherapy and Pharmacology
9. Chemical Engineering Research and Design
10. Current Medicinal Chemistry
11. Evidence-based Complementary and Alternative Medicine
12. Food and Bioprocess Technology
13. Industrial & Engineering Chemistry Research
14. Integrative Biology
15. International Journal of Pharmaceutics
16. Journal of Agricultural and Food Chemistry
17. Journal of Food Biochemistry
18. Journal of Materials Chemistry
19. Oncogene
20. Phytotherapy Research
21. PLoS One
22. Separation and Purification Technology
23. Scientific Reports
24. Soft Matters